Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Effect of Semaglutide on Mortality Outcomes in the FLOW Trial

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

    European Heart Journal Date published:

  • Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

    European Heart Journal Date published:

  • Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial

    Journal of the American College of Cardiology Date published:

  • Kidney Disease as a Cardiovascular Disease Priority

    Circulation Date published:

  • Canagliflozin and iron metabolism in the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

    European Heart Journal Date published:

  • Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease

    NEJM Evidence Date published:

  • Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

    The Lancet Diabetes & Endocrinology Date published:

  • The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials

    Heart, Lung and Circulation Date published:

  • Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

    Circulation Date published:

  • Selonsertib in Patients with Diabetic Kidney Disease

    Journal of the American Society of Nephrology Date published:

  • Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

    New England Journal of Medicine Date published:

  • The Efficacy and Safety of Reduced-Dose Oral Methylprednisolone in High-Risk Immunoglobulin A Nephropathy

    Kidney International Reports Date published:

  • Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

    European Journal of Heart Failure Date published:

  • Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial

    Nature Medicine Date published: